Valion Bio Weighs Strategic Options After Unsolicited Interest in Velocity Bioworks
Valion Bio has received unsolicited acquisition inquiries concerning Velocity Bioworks and is assessing a range of strategic options, including a possible sale.
Valion Bio, Inc. (NASDAQ:VBIO) is evaluating strategic alternatives for its wholly owned contract development and manufacturing organisation, Velocity Bioworks, after receiving unsolicited acquisition inquiries from independent third parties. The company said discussions have begun but remain preliminary, and it has not agreed to sell the subsidiary or pursue another specific transaction.
Valion Bio said it is considering the full range of options for Velocity Bioworks, including a possible sale. Its review will take account of proposed valuation and terms, execution certainty and potential net proceeds.
The company has retained a nationally recognized investment banking firm to advise its Board of Directors on a potential transaction. Valion Bio said there is no assurance that the discussions will produce a definitive agreement or a completed transaction on acceptable terms, or at all.
Any potential transaction would be assessed against Valion Bio’s need to retain production rights and maintain manufacturing capabilities for Entolimod, as well as potentially for other assets in its development pipeline.
Valion Bio said the structure of a sale could provide additional capital for Entolimod’s ongoing development and other corporate priorities, while allowing Velocity Bioworks to operate under new ownership. These outcomes remain dependent on the terms and structure of any transaction, and no transaction has been agreed.
Velocity Bioworks provides biologics development and manufacturing services to Valion Bio and biotechnology companies working on early-stage programmes. Valion Bio said the subsidiary remains operational during the review, while it continues to seek new customer relationships.
The review forms part of the priorities Valion Bio outlined on October 21, 2026. Those priorities include advancing Entolimod and other pipeline assets, expanding Velocity Bioworks’ commercial business and assessing strategic opportunities for the subsidiary.
Valion Bio is developing biologics intended to activate innate immune pathways for cytoprotection and immune modulation. Its lead candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome and has been assessed in animal models under the U.S. Food and Drug Administration’s Animal Rule.
The company is also advancing Entolasta, described as a next-generation Toll-like Receptor 5 agonist, alongside potential programmes involving neutropenia and immune dysfunction. Entolimod has received Fast Track and Orphan Drug designations from the FDA, and Valion Bio holds an exclusive, worldwide licence from Statera Biopharma to develop and commercialise the product for Acute Radiation Syndrome, radiation-induced neutropenia and other indications.
Valion Bio said it does not expect to issue additional updates on the discussions unless a definitive agreement is reached or its Board determines that disclosure is appropriate or legally required.
Valion Bio announced that it had received unsolicited acquisition inquiries from independent third parties concerning its wholly owned contract development and manufacturing organisation, Velocity Bioworks. The company has entered into preliminary discussions while continuing to evaluate a range of strategic options.
Valion Bio announced the unsolicited acquisition inquiries on October 26, 2026. The announcement concerns preliminary discussions and the company's ongoing evaluation of strategic options for Velocity Bioworks.
No, Valion Bio said it has not committed to a sale or any other specific transaction. The discussions remain preliminary, and there is no assurance that they will lead to a definitive agreement or a completed transaction on acceptable terms, or at all.
Valion Bio is evaluating the full range of strategic opportunities for Velocity Bioworks, including a possible sale. The company said it is considering the proposed valuation and terms, execution certainty and potential net proceeds.
Valion Bio said its strategic review is focused on determining how best to maximise the potential of each asset. The review is being conducted alongside priorities including advancing Entolimod and other pipeline assets and building Velocity Bioworks' commercial business.
Interim Chief Executive Officer Dean Zikria said the unsolicited interest provides an opportunity to evaluate a range of strategic options, including a possible sale. He said Valion Bio's priority is identifying the path that best supports its development objectives and delivers long-term value to shareholders.
Yes, Valion Bio said it continues to operate Velocity Bioworks and pursue new customer relationships alongside the discussions with interested parties.
Valion Bio has retained a nationally recognised investment banking firm to act as financial adviser to its Board of Directors in evaluating a potential transaction.
Valion Bio said a key priority is retaining production rights and securing continued manufacturing capabilities for Entolimod and potentially other assets in its development pipeline. The Board will also consider the proposed valuation and terms, execution certainty and potential net proceeds, while further transaction terms may apply.
Valion Bio said a sale, depending on its structure, could provide additional capital for Entolimod's ongoing development and other corporate priorities while positioning Velocity Bioworks for growth under new ownership. The company also said it would prioritise retaining production rights and continued manufacturing capabilities for Entolimod and potentially other pipeline assets.
Valion Bio is a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its lead candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome, while the company is also advancing Entolasta and potential programmes in neutropenia and immune dysfunction.
Valion Bio, Inc. is identified in the release as NASDAQ:VBIO, and the release refers to the continued listing of the company's common stock on the Nasdaq Capital Market.
Valion Bio said it does not expect to provide further updates unless a definitive agreement is reached or its Board determines that disclosure is appropriate or legally required.